In contrast, the folate receptor alpha (FRα) is overexpressed directly on tumor cells in epithelial ovarian cancer, and its selective expression pattern has enabled the development of antibody–drug conjugates (ADCs) for targeted tumor cell elimination (44, 45). Here, FOLR1 is linked to neoplasm.